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 Cancer occurs when the cell does not properly control its own cell cycle. It then 
replicates in an out of control fashion leading to the death of various organs and then the 
demise of the organism as a whole. As it seems to have always been a problem for cell-
based life, certain safeguards against cancer have been evolved over time. One such 
method comes in the form of prevention via cyclin proteins, which are encoded from 
cyclin genes. The gene that is the focus of this research is the CCND1, or cyclin D1, gene 
that controls the progression through various parts of the cell cycle.  
 During the course of research, a portion of the human variant of the protein is ran 
through a database containing all known species that carry a similar gene. After filtering 
for differences, the species were compiled into an ancestry chart. This research could 
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 The goal of this project is to observe how various extracts from thyme (Thymus 
vulgaris), primarily thymol and carvacrol, affects various forms of cancerous cells. These 
phenolic compounds have been associated with biocidal properties, which thyme 
exhibits, and are known as apoptotic regulators, arresting unregulated cell proliferation 
(Sobral, 2014). In this project, we will culture four different cancer cell lines (pancreatic, 
colon, breast, lung) to test the various extracts that thyme is able to produce. Each of 
these extracts have exhibited the ability to induce apoptosis in previous research (Fan K, 
2015), and we hope to build on that research. We will primarily be looking at the genes 
responsible for transcribing proteins responsible for apoptosis (programmed cell death), 
such as BAX and FAS. By targeting these apoptotic regulators, we hope to decipher the 
action of the compounds found in thyme that will lead to the discovery of molecular 
elements in cancer prevention. We hope this will warrant further research into these 
phenolic components.  
 Four different cancer cell cultures will be grown in culture plates (breast, 
pancreatic, colon, and lung). After allowing them to grow for 48 hours, we will add the 
thyme extracts to the wells. We will set up different time frames to add the extracts to the 
wells in intervals of 24, 48, and 72 hours. This will allow us to obtain the cell cultures at 
different stages of cell cycle arrest and growth. We will also have the solvent dimethyl 
sulfide (DMSO) and the reaction buffer phosphate-buffered saline (PBS) alongside the 
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cells that have been treated with the extract to serve as controls. We will, then, harvest 
the cultured cells and extract the RNA that is being transcribed to synthesize cDNA. This 
will be a template for PCR amplification of the BAX and FAS genes. Finally, we will 
look at the results of the PCR amplifications to see if there is a higher, lower, or normal 
expression of each gene in the absence and presence of thymol and carvacrol. This will 
allow us to conclude if these compounds found in thyme are, indeed, effective against 
unregulated cell proliferation and warrant further scientific study.  
 After completing the PCR screenings, we will begin to consolidate the data from 
multiple runs with different DNA primers. By observing this data, we hope to see 
substantial increase in the production of one of the genes being tested. The results will 
show us that an increase in the transcription of these proteins help signal the damaged 
(cancerous) cells to undergo apoptosis via the intrinsic (BAX) or extrinsic (FAS) 
pathway. This will help us understand how we can use the thyme extracts as a potential 
alternative and/or complementary and integrative method of cancer treatment.
.
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CYCLIN D1 EXPLANATION 
  
 Cyclin D1 is a protein encoded by the CCND1 gene on the 11th chromosome and 
belongs to the cyclin family. This gene is involved with regulation of the cell cycle, 
particularly the G1/S transition stage. It has also been shown to have a sustentative role in 
cancer and tumor suppression through its involvement with the tumor suppressor 
retinoblastoma (Rb). When cyclin D1 is observed to be noticeably damaged or mutated, 
there seems to be a strong correlation between its absence and a sharp rise in the 
occurrence of several diseases (Malacards, 2020). Cancer pathways have been observed 
when cyclin D1 has been amplified or overly expressed. In this report, I will explain 
cyclin D1’s origin, class, function, and how its mutation (or lack of function) has a very 
probable chance of developing diseases such as Von Hippel-Lindau syndrome or 
myeloma.   
 Cyclins are a group of vital cell cycle regulators and occur in various types. They 
are generally grouped into one of four categories that represent stages in the cell cycle:  𝐺", 𝐺"/S, S, and M. These categories correspond to the point in the cell cycle at which the 
protein most heavily promotes the changes they are designed to oversee. The proteins 
stay at low levels before their respective cell cycle stage, during which their amount will 
increase (Kahn Academy, 2020). The category most interesting to us is the 𝐺" cyclins, 
since cyclin D1 is a type of 𝐺" cyclin. The portion of the 𝐺" cycle that Cyclin D1 is active
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is quite early on due its relationship to various pathways that kinases set off.  Once 
synthesized, it will have a short half-life due to being regulated by ubiquitination (a 
process involving a regulation protein named ubiquitin) and proteasomal degradation 
(Khan Academy, 2020).  
 Cyclins perform their functions in a CDK, or a cyclin-dependent kinase. To put it 
simply, a kinase is a type of enzyme that phosphorylates, or attaches phosphate groups to, 
specific target proteins. These phosphate groups can make a protein activate its function 
or reduce it. This means that, when they are on their own, these subunits are basically 
inert and harmless. When a CDK meets with its particular cyclin protein, it not only 
achieves its full functionality, but will also direct itself towards activating CDK 
combinations for later stages in the cell’s life cycle (Malumbres, 2014). This makes sense 
since CDK levels will stay mostly the same throughout the cell cycles where they mostly 
have a higher chance of interactions with their namesake cyclin proteins during their 
main phase of activity (Khan Academy, 2020). There are other proteins that work 
together with cyclin D1, such as the aforementioned ubiquitin, retinoblastoma (RB) 
protein—a type of pocket protein that aids in cell cycle regulation—and other types of 
complexes such as CDK inhibitors, which halt the cell cycle when DNA is compromised 
(Du et al., 2013). These processes of cell cycle regulation occur all throughout the 
eukaryotic kingdoms with no known exceptions.   
 Cancer refers to a condition when cells do not obey the correct checkpoints in 
their respective cell cycles and replicate uncontrollably. This state can be induced by a 
lack of cell regulators, like cyclin D1, or an overabundance of checkpoints. Cancer cells 
exhibit abnormal behavior, commonly not needing the body and its various signals to 
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replicate in a culture. They also have the ability to use certain biochemical pathways and 
trick neighboring cells into making growth factors, accelerating their rate of replication. 
They can also commit metastasis and make new blood vessels which spread throughout 
the body and invade other tissues (Khan Academy, 2020). 
 Von Hippel-Lindau syndrome is a hereditary condition that is characterized by the 
growth of tumors (which are not always cancerous) in multiple organs. Regardless of 
their cancer status, these tumors can cause life-threatening complications. They can 
appear in the eyes (causing blindness), central nervous system (headaches and loss of 
nerve functions), and the inner ear tract (hearing and balance loss). In order to combat 
this condition, doctors have relied on cyclin D1 repair, as well as stimulation, to restore 
certain checkpoints within the cell cycle to proper function (Malacards, 2020). 
 Multiple myeloma is a type of cancer that affects blood plasma production. 
When cyclin D1 development is impaired, the body responds by increasing the white 
blood cells, making it the majority of bone marrow cells produced. These tumors make 
bones brittle and can lead to an excess of calcium in the blood, leading to hypercalcemia. 
White blood cells produce proteins that inhibit the growth of red blood cells, which can 
cause people to become anemic (Malacards, 2020).  
 The cancers that originate from an amount of overexpression, or too much 
phosphorylation of the protein, seem to be rarer than cyclin D1’s mutations, with the 
denaturation of this protein being rarer still. Some studies show that denaturation happens 
at around a 2% rate for most cancers and seems to stem from a random switch at codons, 
particularly codon 286 (Xu & Lin, 2018). Another study, which analyzed data from 
hundreds of studies, concluded that CCND1’s rate of overexpression is approximately 
 6 
4%, with CCND1 mutation occurring in 0.5% of the studied cases and theorized that the 
mutation would be predominately found in tumors of origin. Most defects in cyclin D1 
seems to be in the c-terminus of the protein (Xu & Lin, 2018). This, in turn, causes the 
CDK 4/6 to be more active throughout all of the cell cycle, making tumorigenesis and 
cell proliferations more likely.  
 In regard to endometrial cancer, c-terminal mutations involving Thr286 and 
Pro287 appear to be a driving force in increasing nuclear accumulation of cyclin D1, 
gain-of-function, and cellular transformation (Xu & Lin, 2018). Although there is no 
FDA-official cure for cyclin D1 defective cancers, there is some hope. There has been 
some headway made in cures involving CDK 4/6 inhibition, as well as preventative 
CCND1 gene therapy (Sobral et al., 2014).
 7 
MY CONTRIBUTION 
 The purpose of this study is to study the cyclin D1 (CCND1) gene, which is a 
vital part of cell cycle regulation and has been shown to be a tumor suppressor. The goal 
of this study is to gain an understanding of CCND1’s evolutionary history across species.  
 Using PSI-BLAST software, the gene sequence from humans was compared with 
homologous sequences from other species; the information drawn from the comparison 
was used to create a neighbor-joining phylogenetic tree (see Figure 1). The big-headed 
turtle (Platysternon megacephalum) was the most ancient identifiable species—with it 
being represented as the center dot of the tree—whereas the ring-necked pheasant 
(Phasianus colchicus) is the most recently developed species, as it is the outer-most split 
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>XP_029702239.1 G1/S-specific cyclin-D1 [Takifugu rubripes] 
MGEKLLCCEVDSIRRAYQDANLLNDRVLLTMLKAEEHYLPSPNYFKCVQKELVP
KMRKIAATWMLEVCEE 
QKCEEEVFPLAMNYLDRFLSVEATSKTRLQLLGATCMFLASKMKETVPLSVEKL
CIYTDNSVHPGELLQM 
ELLVLSKLKWDLASVMPHDFIEHFLSKLRIFPSTKHILRKHAQTFVALCATDVNFI
ASPPSMVAAGSVVA 
AVQGLYLKSLDASFSSQNLTNLLSQVIGSDPDCLRACQEQIESLLESSLQQVQHH
NNTKEPKCVASDADL 
SCTPTDVRDINI 
